Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alienys Izquierdo is active.

Publication


Featured researches published by Alienys Izquierdo.


Antiviral Research | 2008

Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates

Lidice Bernardo; Alienys Izquierdo; Mayling Alvarez; Delfina Rosario; Irina Prado; Carlos López; Rafael Galera Martínez; Jorge Jiménez Castro; Emidalys Santana; Lisset Hermida; Gerardo Guillén; María G. Guzmán

Recombinant fusion proteins containing the aa 286-426 of the dengue envelope protein fused to P64k protein from Neisseria meningitidis have been previously reported. Particularly, the immunogenicity and protective capacity of the dengue 2 recombinant protein was demonstrated in Macaca fascicularis monkeys. Here we evaluate the recombinant fusion protein containing the domain III of the dengue 1 envelope protein (PD10) in non-human primates (M. fascicularis and rhesus monkeys) and compare the effect of aluminum hydroxide and Freund adjuvant on the immunity induced. The PD10 protein emulsified in Freund adjuvant was highly immunogenic in M. fascicularis and rhesus monkeys. Following dengue 1 virus challenge, animals immunized with PD10 in Freund adjuvant were protected from viremia. However, monkeys receiving PD10 in aluminum hydroxide developed a poor antibody response and were not protected from viral challenge. These preliminary experiments are encouraging. Other formulations or vaccine schedules are being studied in an attempt to find regimens that enhance immunological protection.


American Journal of Tropical Medicine and Hygiene | 2010

Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcγRIIa polymorphism.

Gissel García; Beatriz Sierra; Ana B. Pérez; Eglys Aguirre; Ileana Rosado; Narjara González; Alienys Izquierdo; Maritza Pupo; Didye Ruiz Danay Díaz; Lizet Sánchez; Beatriz Marcheco; Kenji Hirayama; María G. Guzmán

The role of human Fcgamma receptors (FcgammaR) has been recognized considerably over the last years. These receptors vary in their affinity for IgG subclasses and the intracellular signals elicited by them. Allelic variants of FcgammaR genes may influence the biological phagocyte activity, accounting for an inherited pre-disposition to disease. The specific FcgammaRIIa (CD32) contains a polymorphic variant (H/R131) that has been associated to a reduced risk for developing dengue hemorrhagic fever (DHF). Here, we investigated the role of this polymorphism in a very well-characterized group of Cuban individuals with antecedents of DHF, dengue fever (DF), or subclinical dengue infection. The HH131 genotype was significantly associated with dengue disease, either DF (*P = 0.016; odds ratio = 4.425; 95% confidence interval = 1.10-20.52) or DHF (P = 0.00018; odds ratio = 10.56; 95% confidence interval = 2.33-54.64) with respect to the subclinical infection.


International Journal of Infectious Diseases | 2011

Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders

Gissel García; Narjara González; Ana B. Pérez; Beatriz Sierra; E. Aguirre; Damaris Rizo; Alienys Izquierdo; Lizet Sánchez; Danay Díaz; Magnolia Lezcay; Betsi Pacheco; Kenji Hirayama; María G. Guzmán

OBJECTIVES The acute manifestations of dengue are well known. The clinical symptoms that present during the convalescent phase of infection are less well characterized, but may be autoimmune-based. This study was undertaken to determine the prevalence of persistent clinical symptoms among individuals infected during the 2006 Cuban epidemic and to evaluate the immunological and genetic factors associated with their occurrence. METHODS In 2008, clinical data and blood samples were collected from a random sample of adult individuals diagnosed during the 2006 epidemic with dengue fever (DF, n=68), dengue hemorrhagic fever (DHF, n=29), or an asymptomatic infection (AI, n=42). The presence of persistent symptoms was evaluated in all individuals and a psychological assessment was performed. IgG titers and the Fc receptor (FcR) were also evaluated. The following autoimmune markers were assessed in a subset (n=26) of symptomatic individuals: complement factors C3/C4, rheumatoid factor (RF), C-reactive protein (CRP), antinuclear antibodies (ANA), and immune complex (IC). RESULTS Over half (55/97) the individuals with a prior of diagnosis of DF or DHF had persistent clinical symptoms in the 2 years following infection. The sequelae were unrelated to the initial diagnosis and were more common among women (44/55). No symptoms were reported in the AI group and all study participants had normal mental and cognitive function. Persistent clinical symptoms were associated with HH polymorphic variant (p=0.027) and high IgG titer (p=0.041). Autoimmune marker alterations were common (20/26) in the subset of symptomatic individuals evaluated. CONCLUSIONS Clinical sequelae after recovery from an acute dengue virus infection are common in the 2 years following infection. The results obtained in this study suggest that persistent symptoms are associated with alterations in some immunological parameters and FcγRIIa gene polymorphism. This could suggest an autoimmune-based disturbance.


Clinical and Vaccine Immunology | 2008

Primary and Secondary Infections of Macaca fascicularis Monkeys with Asian and American Genotypes of Dengue Virus 2

Lidice Bernardo; Alienys Izquierdo; Irina Prado; Delfina Rosario; Mayling Alvarez; Emidalys Santana; Jorge Rey de Castro; Rafael Rodríguez Martínez; Rosmari Rodríguez; Luis Morier; Gerardo Guillén; María G. Guzmán

ABSTRACT The goal of this study was to compare the immune response and the protection capacity induced by the dengue virus 2 (DENV-2) American and Asian genotypes in Macaca fascicularis monkeys. Animals were infected with American or Asian DENV-2 strains and challenged 1 year later with a DENV-2 Asian genotype strain. The viremia and monkey antibody levels were similar for the different strains after primary and secondary infection; however, the functionality of the antibody response was different. A limited viral replication was demonstrated after the secondary infection in all the monkeys. No virus was isolated in tissue culture, while reverse transcription-PCR showed a late positive reaction in four of five challenged monkeys. The immunoglobulin M response pattern and the detection of antibodies to specific proteins by Western blotting supported the protection data. Despite the demonstration of the protective effect after homologous challenge, a strong anamnestic antibody response was observed.


Journal of General Virology | 2012

Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice

Lázaro Gil; Lidice Bernardo; Alequis Pavón; Alienys Izquierdo; Iris Valdés; Laura Lazo; Ernesto Marcos; Yaremis Romero; María G. Guzmán; Gerardo Guillén; Lisset Hermida

The interplay of different inflammatory cytokines induced during dengue virus infection plays a role in either protection or increased disease severity. In this sense, vaccine strategies incorporating whole virus are able to elicit both functional and pathological responses. Therefore, an ideal tetravalent vaccine candidate against dengue should be focused on serotype-specific sequences. In the present work, a new formulation of nucleocapsid-like particles (NLPs) obtained from the recombinant dengue-2 capsid protein was evaluated in mice to determine the level of protection against homologous and heterologous viral challenge and to measure the cytotoxicity and cytokine-secretion profiles induced upon heterologous viral stimulation. As a result, a significant protection rate was achieved after challenge with lethal dengue-2 virus, which was dependent on CD4(+) and CD8(+) cells. In turn, no protection was observed after heterologous challenge. In accordance, in vitro-stimulated spleen cells from mice immunized with NLPs from the four dengue serotypes showed a serotype-specific response of gamma interferon- and tumour necrosis factor alpha-secreting cells. A similar pattern was detected when spleen cells from dengue-immunized animals were stimulated with the capsid protein. Taking these data together, we can assert that NLPs constitute an attractive vaccine candidate against dengue. They induce a functional immune response mediated by CD4(+) and CD8(+) cells in mice, which is protective against viral challenge. In turn, they are potentially safe due to two important facts: induction of serotype specific cell-mediated immunity and lack of induction of antiviral antibodies. Further studies in non-human primates or humanized mice should be carried out to elucidate the usefulness of the NLPs as a potential vaccine candidate against dengue disease.


Virus Research | 2008

Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus.

Alienys Izquierdo; Lidice Bernardo; Emidalys Santana; Lisset Hermida; Gerardo Guillén; María G. Guzmán

Here, the antigenic specificity of the recombinant fusion proteins containing aa 286-426 of the dengue envelope protein fused to P64k from Neisseria meningitidis and the cross-reactive antibody response induced in immunized mice and monkeys were evaluated. The anti-dengue mice antibodies showed a higher reactivity to the homologous recombinant proteins compared to the wide cross-reactivity observed by dot blot to the viral antigens. The immune response induced by the recombinant proteins in mice and monkeys, was highly serotype specific. The serotype-specificity associated with these recombinant proteins in addition to the high antigenicity, immunogenicity and protecting capacity suggest their advantages as possible vaccine candidates.


Immunology and Cell Biology | 2015

The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2

Lázaro Gil; Ernesto Marcos; Alienys Izquierdo; Laura Lazo; Iris Valdés; Peris Ambala; Lucy Ochola; Rikoi Hitler; Edith Suzarte; Mayling Alvarez; Prisilla Kimiti; James Ndung'u; Thomas Kariuki; María G. Guzmán; Gerardo Guillén; Lisset Hermida

Previously, we reported the ability of the chimeric protein DIIIC‐2 (domain III of the dengue envelope protein fused to the capsid protein of dengue‐2 virus), to induce immunity and protection in mice, when it is highly aggregated with a non‐defined oligodeoxynucleotide (ODN) and adjuvanted in alum. In this work, three different defined ODNs were studied as aggregating agents. Our results suggest that the nature of the ODN influences the capacity of protein DIIIC‐2 to activate cell‐mediated immunity in mice. Consequently, the ODN 39M was selected to perform further experiments in mice and nonhuman primates. Mice receiving the preparation 39M‐DIIIC‐2 were solidly protected against dengue virus (DENV) challenge. Moreover, monkeys immunized with the same preparation developed neutralizing antibodies, as measured by four different neutralization tests varying the virus strains and the cell lines used. Two of the immunized monkeys were completely protected against challenge, whereas the third animal had a single day of low‐titer viremia. This is the first work describing the induction of short‐term protection in monkeys by a formulation that is suitable for human use combining a recombinant protein from DENV with alum.


Virology | 2014

Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.

Lázaro Gil; Alienys Izquierdo; Laura Lazo; Iris Valdés; Peris Ambala; Lucy Ochola; Ernesto Marcos; Edith Suzarte; Thomas Kariuki; Guadalupe Guzmán; Gerardo Guillén; Lisset Hermida

The role of cellular immune response in dengue virus infection is not yet fully understood. Only few studies in murine models propose that CD8(+) T-cells are associated with protection from infection and disease. At the light of recent reports about the protective role of CD8(+) T-cells in humans and the no correlation between neutralizing antibodies and protection observed in several studies, a vaccine based on cell-mediated immunity constitute an attractive approach. Our group has developed a capsid-based vaccine as nucleocpasid-like particles from dengue-2 virus, which induced a protective CD4(+) and CD8(+) cell-mediated immunity in mice, without the contribution of neutralizing antibodies. Herein we evaluated the immunogenicity and protective efficacy of this molecule in monkeys. Neither IgG antibodies against the whole virus nor neutralizing antibodies were elicited after the antigen inoculation. However, animals developed a cell-mediated immunity, measured by gamma interferon secretion and cytotoxic capacity. Although only one out of three vaccinated animals was fully protected against viral challenge, a viral load reduction was observed in this group compared with the placebo one, suggesting that capsid could be the base on an attractive vaccine against dengue.


International Immunology | 2015

A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.

Edith Suzarte; Lázaro Gil; Iris Valdés; Ernesto Marcos; Laura Lazo; Alienys Izquierdo; Angélica García; Lázaro López; Maylin Álvarez; Yusleydis Pérez; Jorge Fernandez de Castro; Yaremis Romero; María G. Guzmán; Gerardo Guillén; Lisset Hermida

Our group developed a subunit vaccine candidate against dengue virus based on two different viral regions: the domain III of the envelope protein and the capsid protein. The novel chimeric protein from dengue-2 virus [domain III-capsid (DIIIC-2)], when presented as aggregated incorporating oligodeoxynucleotides, induced anti-viral and neutralizing antibodies, a cellular immune response and conferred significant protection to mice and monkeys. The remaining constructs were already obtained and properly characterized. Based on this evidence, this work was aimed at assessing the immune response in mice of the chimeric proteins DIIIC of each serotype, as monovalent and tetravalent formulations. Here, we demonstrated the immunogenicity of each protein in terms of humoral and cell-mediated immunity, without antigen competition on the mixture forming the formulation tetra DIIIC. Accordingly, significant protection was afforded as measured by the limited viral load in the mouse encephalitis model. The assessment of the tetravalent formulation in non-human primates was also conducted. In this animal model, it was demonstrated that the formulation induced neutralizing antibodies and memory cell-mediated immune response with IFN-γ-secreting and cytotoxic capacity, regardless the route of immunization used. Taken together, we can assert that the tetravalent formulation of DIIIC proteins constitutes a promising vaccine candidate against dengue virus, and propose it for further efficacy experiments in monkeys or in the dengue human infection model, as it has been recently proposed.


Antiviral Research | 2012

Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2

Alienys Izquierdo; Iris Valdés; Lázaro Gil; Lisset Hermida; Sheila Gutiérrez; Angélica García; Lidice Bernardo; Alekis Pavón; Gerardo Guillén; María G. Guzmán

Recombinant fusion protein containing domain III of the dengue envelope protein fused to capsid protein from dengue 2 virus was immunogenic and conferred protection in mice against lethal challenge in previously report. Here, the antigenic specificity of this recombinant protein using anti-dengue antibodies from mice and humans and the cross-reactive humoral and cellular response induced in immunized mice were evaluated. The homologous anti-dengue antibodies showed a higher reactivity to the recombinant protein compared to the wide cross-reactivity observed for viral antigen as determined by ELISA. The IgG anti-dengue and functional antibodies, induced by the recombinant proteins in mice, were highly serotype specific by ELISA, hemaglutination inhibition and plaque reduction neutralizing tests. Accordingly, the cellular immune response determined by the IFNγ and TNFα secretion, was serotype specific. The specificity of serotype associated to this recombinant protein in addition to its high antigenicity, immunogenicity and protecting capacity suggest its advantage as a possible functional and safe vaccine candidate against dengue in a future tetravalent formulation.

Collaboration


Dive into the Alienys Izquierdo's collaboration.

Top Co-Authors

Avatar

María G. Guzmán

Pan American Health Organization

View shared research outputs
Top Co-Authors

Avatar

Mayling Alvarez

Pan American Health Organization

View shared research outputs
Top Co-Authors

Avatar

Angélica García

Pan American Health Organization

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ana B. Pérez

International Centre for Genetic Engineering and Biotechnology

View shared research outputs
Top Co-Authors

Avatar

Lizet Sánchez

Center of Molecular Immunology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carlos López

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge